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1 Introduction 
1.1 The incretin effect and the discovery of GLP-1 
Studies concerning an endocrine activity of the gastrointestinal tract started 
around the beginning of the 20th century with the discovery of gut hormones such 
as secretin by Bayliss and Starling [1]. Glucose-lowering effects of duodenal 
mucosa extracts was shown as early as 1906 by Moore et al. [2]. The term 
“incretin” for gut derived substances that lower blood glucose was first introduced 
by La Barre in 1932 [3]. The development of a radioimmunoassay for insulin 
allowed the demonstration of the so-called “incretin effect” by showing that 
glucose administered orally stimulated a greater insulin response than if 
administered intravenously [4, 5].  
In healthy individuals the incretin effect accounts for 50-70% of postprandial 
insulin secretion [6], whereas this effect is reduced in patients with type 2 
diabetes (T2D) and subjects at risk for developing diabetes [7, 8]. Two hormones 
have been identified that mediate the majority of the incretin effect: Glucagon-like 
peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), 
hence called incretins or incretin hormones.  
GIP was extracted from duodenal mucosa of pigs in the early 1970s by the group 
of John Brown in Vancouver [9, 10]. Initially it was termed gastric inhibitory 
polypeptide, because it reduced gastric acid secretion in dogs. However, this 
occurs only at pharmacological doses, whereas purified preparations of GIP were 
shown to potently augment glucose-stimulated insulin secretion in humans [11] 
and rats [12]. It was later revealed that GIP is secreted from enteroendocrine K-
cells within the mucosa of the stomach and duodenum in response to luminal 
nutrients and has a variety of biological actions beyond its action as an incretin. 
Among these GIP is known to induce glucagon secretion, inhibit apoptosis in the 
pancreatic -cells and promote their proliferation, as well as to induce fat 
deposition in adipose tissue. Furthermore, GIP is involved in bone metabolism 
[6]. Although GIP was soon recognized as a mediator of the incretin effect it 
became quickly evident that GIP was not the only incretin [13]. 
In the 1980s GLP-1 was discovered by cDNA sequencing of proglucagon mRNA 
[14]. Glucagon is a peptide with 29 amino acids that is spliced from a much larger 
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proglucagon protein with 158 amino acids (figure 1). Next to glucagon other 
peptide fragments, namely glicentin related pancreatic polypeptide (GRPP), 
intervening peptide 1 (IP1), and major proglucagon fragment (MPGF) are 
included in the proglucagon transcript of the pancreas. Within the MPGF two 
glucagon-like sequences were found and named GLP-1 and glucagon-like 
peptide-2 (GLP-2), respectively. Peptide sequencing suggested that GLP-1 would 
be cleaved in position 72 of proglucagon, where two consecutive basic amino 
acids are encoded and thus consists of 37 amino acids (GLP-1(1-37)) (figure 1) 
[14]. Further research revealed that only the truncated form of the peptide 
cleaved at another basic amino acid in position 77, followed by a histidine in 
position 78, called GLP-1(7-37), is bioactive and stimulates cAMP production and 
insulin release in rat islet cells [15]. Moreover, the c-terminal peptide sequence 
predicts a prohormone convertase–directed cleavage site followed by an 
amidation of the penultimate arginine resulting in GLP-1(1-36)amide and GLP-
1(7-36)amide, respectively. Until today no bioactivity has been shown for the non-
truncated forms GLP-1(1-37) and GLP-1(1-36)amide [14]. 
It had been known for some time that a so-called “gut glucagon” existed [16], and 
it was suspected that it contributed to hyperinsulinemic reactive hypoglycemia 
seen after gastric surgery [17]. However, it was found that the immunoreactivity 
for glucagon in the gut came from a larger peptide that included the sequence of 
glucagon, called glicentin (figure 1) [18]. Because all the components for glicentin 
and glucagon were both present in the pancreas and the intestine, it was 
suspected that differential processing in the various tissues is responsible for the 
different peptide products [14]. Because neither glicentin nor the other peptide 
within the glicentin fragment, oxyntomodulin (OXM), has significant insulinotropic 
potency, the focus shifted towards the MPGF and the two glucagon-like peptides 
expressed within this fragment.  
The discovery that GLP-1(7-37) produced in the gut of various mammals is a 
potent stimulus for insulin secretion in rats [19], pigs [20], and humans [21] was a 
major breakthrough in 1987. Henceforth, GLP-1 was recognized as the second 
incretin along with GIP, and became the topic of intensive research about its 
physiological and pharmacological actions [14]. 
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We know today, that the preproglucagon gene is expressed in the pancreatic α-
cells, enteroendocrine L-cells of the gut and the central nervous system (CNS), 
namely neurons within the nucleus of the solitary tract [22]. Differential splicing by 
enzymes called prohormone convertase 1/3 (PC1/3; gut, brain) and prohormone 
convertase 2 (PC2; α-cell) results in tissue specific posttranslational processing. 
The α-cell produces predominantly glucagon, along with GRPP, IP1 and MPGF. 
In the L-cells and the brain cleavage of proglucagon by PC1/3 yields the peptides 
GLP-1, GLP-2, OXM, intervening peptide 2 (IP2), and glicentin (figure 1). The 
latter two products have no known biological function [22]. GLP-2 has potent 
intestinotrophic properties and has been developed into a treatment for short-
bowel syndrome [14]. OXM has weak agonistic activity at the glucagon (Gcgr) 
and GLP-1 receptors (GLP-1r) without a known receptor of its own and its 
biological importance is unclear. More recently it has been suggested to be used 
as a co-agonist with GLP-1 to treat diabetes and obesity [23]. Newer studies 
Figure 1: Proglucagon and its cleavage products by tissue specific 
differential splicing (from Drucker et al. 2017 [14]). In the intestine (and brain) 
activity of prohormone convertase 1/3 (PC1) results in production of glicentin, 
oxyntomodulin, GLP-1, GLP-2, and intervening peptide-2 (IP-2). In the pancreas 
proglucagon is processed into glucagon, glicentin related pancreatic polypeptide 
(GRPP), intervening peptide-1 (IP-1), and major proglucagon fragment (MPGF) 
by prohormone convertase 2 (PC2). 
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suggest that splicing of proglucagon in the pancreas does not exclusively result in 
glucagon production but small amounts of PC2 are also present within the α-cell 
[22]. 
Enteroendocrine L-cells are present in the small and large intestine, where 
nutrients within the lumen of the gut stimulate rapid secretion of GLP-1 into the 
circulation. Within the intestine, the density of glucagon gene expression and 
proglucagon synthesis increases from the proximal to distal gut and expression is 
highest in the colon. Besides luminal contact of nutrients with the L-cells, also 
neural, endocrine, and paracrine mechanisms are suggested to be involved in 
GLP-1 secretion [22]. Both, GLP-1(7-37) and GLP-1(7-36)amide, are secreted 
from the intestine with GLP-1(7-36)amide representing the major form of active 
GLP-1 in human plasma [24]. There is no evidence towards a differential effect or 
potency of the amidated and non-amidated form of GLP-1 [14]. GLP-2 is secreted 
along with GLP-1 in equimolar amounts from intestinal L-cells. 
1.2 Biological actions of GLP-1 
Because GLP-1 was expected to act as an incretin hormone, its glucose-
dependent insulinotropic properties were revealed as soon as the functional 
peptide was discovered. However, numerous biological actions of GLP-1 beyond 
insulin secretion have since been identified. GLP-1 mediates its effects via a 
specific receptor expressed in a variety of tissues.  
The GLP-1r is a 7-transmembrane-spanning, heterotrimeric G-protein-coupled 
receptor from the same family as the receptors for glucagon, GLP-2, and GIP. Its 
expression was confirmed in various tissues including the pancreatic α, β, and δ-
cells, lung, heart, kidney, intestine, and parts of the central and peripheral 
nervous system [6]. Mice with a deleted GLP-1r gene (GLP-1r -/-) or a lack of the 
preproglucagon gene (Gcg -/-) have been particularly helpful in unravelling the 
physiology of GLP-1. Similarly, the use of a specific GLP-1r antagonist 
exendin(9-39), the truncated form of the naturally occurring GLP-1r agonist 
exendin-4, in humans has contributed significantly to understanding the 
importance of GLP-1 in health and disease [25]. 
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A summary of the most prominent biological actions of GLP-1 is outlined in 
figure 2 [24]. Most is known about the physiological role and molecular 
mechanisms of the GLP-1r in the pancreatic β-cell, from where the receptor was 
initially cloned. In the islets of Langerhans, GLP-1 also reduces glucagon 
secretion from α-cells, stimulates insulin biosynthesis and enlarges β-cell mass in 
Figure 2: Direct and indirect effects of GLP-1 action in different target 
tissues (from Baggio and Drucker 2007 [6]). GLP-1r signaling has direct 
effects in different target tissues like the pancreatic islets, stomach and intestine, 
central nervous system and the heart. Other effects like glucose lowering actions 
in the liver, muscle and adipose tissues seem to be mediated indirectly through 
neural pathways. 
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rodents by increased proliferation and downregulation of apoptosis. However, the 
latter effects are only seen in preclinical studies and experiments in humans have 
failed to show an enlargement of β-cell mass or persistent improvement in β-cell 
function in diabetic patients after treatment with GLP-1-based pharmacotherapies 
[26].  
Other glucoregulatory actions of GLP-1 include enhancement of hepatoportal 
glucose sensing, reduction of hepatic glucose production and increased 
peripheral insulin sensitivity. Because liver, adipose tissue, and muscle do not 
conclusively express the GLP-1r, these actions seem to be mediated indirectly 
through neural mechanisms [26].  
GLP-1r -/- mice show impairment of glucose tolerance and reduced glucose-
stimulated insulin secretion [27]. Interestingly, these mice also have increased 
fasting glycemia, proving that the glucoregulatory actions of GLP-1 are not limited 
to the postprandial phase. In humans, acute antagonism of the GLP-1r with 
exendin-(9-39) results in impaired glucose tolerance and reduced insulin 
secretion along with an increase of glucagon [28, 29]. Thus, GLP-1 is a 
physiological regulator of glucose metabolism in rodents and humans.  
Other prominent actions of GLP-1r signaling include inhibition of gastric 
emptying, increased satiety with reduction of food intake and weight loss, as well 
as cardio- and neuroprotective effects [6]. However, these effects are much more 
prominently seen during pharmacological interventions using supraphysiologic 
doses of native GLP-1 or GLP-1r agonists [30]. Particularly the effects on body 
weight and cardiovascular function have not consistently been shown to be 
physiologically regulated by GLP-1 in humans. On the other hand, these actions 
explain very well the prominent side-effects of GLP-1r agonists in the treatment of 
diabetes. While some of these effects are favorable (weight loss, cardiovascular 
benefits) others limit the clinical use in some patients (nausea, vomiting) [26].  
GLP-1 actions in the heart are complex and the GLP-1r seems to be expressed 
in different cell types of the rodent and human heart [31]. In addition, cardiac 
effects of GLP-1 have been shown in GLP-1r -/- mice and with GLP-1r blockade 
suggesting some receptor independent effects. At least in rodents GLP-1 seems 
to improve ventricular function and plays a potentially physiologic role [31]. 
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However, in humans there was no clinical benefit of chronic GLP-1r activation in 
patients with congestive heart failure [32]. The cardiovascular biology of GLP-1 
has been extensively reviewed by Ussher and Drucker in 2012 [31] and Drucker 
in 2016 [33]. More recently, the reduced rate of cardiovascular events and 
mortality in diabetic patients treated with the GLP-1r agonists liraglutide [34] and 
semaglutide [35] has further triggered interest in the cardioprotective properties of 
GLP-1 [32].  
Although GLP-1r expression is abundant in the lung the precise function of GLP-
1 in the respiratory system and its relevance to normal pulmonary physiology are 
not known [6]. While the GLP-1r mRNA transcripts are found in the kidney the 
precise cellular localization is not yet revealed. Infusion of GLP-1 into rodents and 
humans evokes a natriuretic and diuretic response. Nevertheless, there is little 
compelling evidence implicating a protective role for GLP-1r agonists in the 
kidney [30]. Newer research suggests a role of GLP-1 in the immune system and 
inflammation. The GLP-1r is also expressed in intraepithelial lymphocytes and 
there seems to be interaction with the gut microbiome. However, a physiological 
or pharmacological relevance of these findings in humans has not yet been 
established [26].  
1.3 Rapid degradation of GLP-1 (and GIP) by Dipeptidylpeptidase-IV 
(DPP-IV) 
The glucose-lowering and anorectic effects of GLP-1 have soon generated great 
interest into developing the incretins into a pharmacotherapy for diabetes and 
obesity. However, native GLP-1 has a dramatically short half-life of 60-
90 seconds in vivo. This is due to rapid cleavage of the first two amino acids 
histidine-7 and alanine-8 of the peptide by the ubiquitous enzyme DPP-IV [36]. 
Thus, the vast majority of circulating GLP-1 is comprised of the non-insulinotropic 
cleavage product GLP-1(9-36) [37]. Until today, there is an ongoing debate 
whether GLP-1(9-36) has important biological actions. However, it is generally 
accepted that DPP-IV inactivated GLP-1 does not act as an incretin hormone 
[38]. Similarly GIP is cleaved after the first two n-terminal amino acids and 
inactivated by DPP-IV with a slightly longer circulating half-life of 5-7 minutes 
[39].  
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DPP-IV, also known as CD-26, is ubiquitously expressed in a variety of tissues. It 
exists in two different forms, a membrane bound receptor protein stimulating 
intracellular signaling pathways, and as soluble DPP-IV (sDPP-IV) found in the 
circulation of various mammals, including humans and rodents. Both forms of 
DPP-IV retain their enzymatic activity [24]. CD-26 seems to have an important 
role as signaling pathway of the immune system and is best characterized in T-
cells. Despite this, the immunological phenotype of DPP-IV -/- mice is 
astonishingly benign without any major defect in immune function [40, 41].  
On the other hand, the role of DPP-IV activity in regard to glucose homeostasis 
has been extensively studied and DPP-IV loss-of-function models helped greatly 
to understand the physiology of the enzymatic component. DPP-IV -/- mice as 
well as a naturally occurring strain of Fisher 344 rats with absent or reduced 
activity of DPP-IV show improved glycemic control, elevated insulin levels as well 
as reduced degradation of GIP and GLP-1 [40, 42]. Furthermore, DPP-IV null 
mice are protected from obesity and insulin resistance induced by a high-fat diet 
[43].  
Pharmacological inhibition of DPP-IV activity also results in prolonged half-life of 
the incretins GLP-1 and GIP and a reduction of hyperglycemia with an 
enhancement of glucose-stimulated insulin release [6]. Furthermore, the 
metabolic actions of DPP-IV inhibitors seem to be exclusively mediated by GLP-1 
and GIP as the disruption of both their signaling in a dual incretin receptor 
knockout mouse (DIRKO) abolishes the metabolic actions of DPP-IV inhibitors 
like vildagliptin [44]. 
In addition to DPP-IV various other peptidases and renal clearance play a role in 
the clearance of GLP-1 and GIP but to a much lesser extent.  
1.4 Pharmacotherapies based on the incretin system 
The potential of GLP-1 as diabetes therapy was soon recognized and generated 
great interest in how to exploit the incretin system for pharmaceutical purposes. 
The combination of the glucose-lowering actions of GLP-1 with little risk of 
hypoglycemia and concomitant weight-loss promised superiority to any previously 
established pharmacotherapy of diabetes.  
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A fundamental observation driving much of the research into GLP-1 action was 
the blunted incretin effect in patients with T2D [7]. While the responsiveness of β-
cells to GIP is severely attenuated in diabetic patients, GLP-1 retains its 
insulinotropic actions and lowers glycemia [45]. Hence forth the majority of 
studies exploring the incretin system as a therapy for diabetes have focused on 
GLP-1 [25]. In a proof-of-concept study, continuous subcutaneous infusion of 
GLP-1 in diabetic patients over 6 weeks resulted in a reduction of HbA1c of 1.3% 
and a weight loss of 1.9 kg [46]. However, the rapid degradation of native GLP-1 
by DPP-IV and the parenteral administration route limited GLP-1 as a feasible 
long-term therapy for diabetic patients.  
John Eng explored the biological actions of peptides extracted from the 
venomous saliva of the lizard Heloderma suspectum in his laboratory. The 
extracted peptide exendin-4 shows 50% homology with the amino acid sequence 
of mammalian GLP-1 and acts as an agonist on the GLP-1r [47, 48]. Because it 
does not share the alanine in position two of the N-terminus, exendin-4 is 
resistant to degradation by DPP-IV. It was proven useful in the treatment of T2D 
as a subcutaneous injection and approved by the US Food and Drug 
Administration in 2005 under the name exenatide [25]. Other specifically 
designed GLP-1r agonists with long-term stability and resistance to DPP-IV 
degradation have followed since and proven helpful pharmacologic agents in 
T2D. Particularly the reduction of cardiovascular events and mortality by some 
agents in this drug class has underlined the potential of the GLP-1r agonists for 
the treatment of T2D. To date there are only two established drug classes in 
diabetes therapy with proven cardiovascular benefits [32]. In 2014 the GLP-1r 
agonist liraglutide has been approved for the treatment of obesity in non-diabetic 
patients [49]. Currently dual agonists of the GLP-1 and GIP receptors are 
developed into novel diabetes and obesity therapeutics and show superior 
efficacy compared to agonists of the GLP-1r alone [50-52]. 
Another mechanism to exploit the incretin system as a diabetes therapy is 
preventing the degradation of endogenous GLP-1 and GIP by inhibition of DPP-
IV. As can be expected circulating concentrations of non-degraded active forms 
of both incretins are increased with pharmacologic inhibition of DPP-IV [53]. This 
results in a reduction of fasting and postprandial hyperglycemia in patients with 
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T2D by enhanced glucose-stimulated insulin secretion from β-cells and 
suppression of glucagon [25]. The first DPP-IV inhibitor approved for the 
treatment of T2D by the US Food and Drug Administration was sitagliptin in 2006. 
Multiple other substances in this drug-class have since been approved and are 
available for treatment of diabetes [14].  
Unlike GLP-1r agonists, treatment with DPP-IV inhibitors has a neutral effect on 
body weight and does not impact clinically significant gastric emptying. A great 
advantage of DPP-IV inhibitors in the treatment of diabetes is the convenient oral 
administration of the small-molecule enzyme inhibitors and the lack of clinically 
relevant adverse events in the majority of patients (except for mild 
gastrointestinal side effects). Because the insulinotropic and glucagonostatic 
effects are mediated through the incretins in a glucose-dependent manner, there 
is practically no risk of hypoglycemia with these agents [25]. However, the 
relative potency to lower glycemia measured by HbA1c is somewhat weaker than 
that seen with GLP-1r agonists and the weight neutrality of this drug-class makes 
it less favorable for obese or overweight diabetic patients [54]. Furthermore, none 
of the many DPP-IV inhibitors licensed for therapy have proven cardiovascular 
benefits compared to standard treatment of diabetes [32].  
GLP-1r agonists and DPP-IV inhibitors show distinct differences in their 
therapeutic actions. While DPP-IV inhibition results in significant but small 
increase of active GLP-1 (and GIP) plasma concentrations with a reduction of 
total circulating GLP-1 (mediated through a putative feed-back inhibition on L-
cells), injection of GLP-1r agonists results in potent and supraphysiologic 
stimulation of GLP-1r in all compartments and tissues expressing the receptor. 
This underlines the importance to differentiate between physiologic and 
pharmacologic GLP-1 actions [54]. 
1.5 Evidence of a non-humoral mechanism of action of GLP-1 to 
release insulin secretion 
In healthy humans glycemia is very tightly regulated despite major challenges 
through nutrient and carbohydrate ingestion and phases of intermittent or 
prolonged fasting. Increasing meal-sizes lead to a larger insulin release despite 
very similar glycemic excursions and this feed-forward mechanism is thought to 
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be regulated by the incretins. The classical model of incretin action is that GLP-1 
and GIP get secreted from intestinal endocrine cells into the circulation in 
response to nutrients. From there the incretin hormones reach the pancreatic β-
cell with its specific receptors and stimulate insulin release in a glucose-
dependent manner [55].  
To maintain tight glycemic control plasma insulin concentrations underlie a wide 
dynamic range with more than 10-fold differences between the fasting and 
postprandial state. Similarly, plasma levels of GIP have a similar broad 
physiological range, with levels increasing 5-10 fold over fasting after meals. On 
the other hand, GLP-1 concentrations in the circulation are very low and barely 
detectable in the fasting state and increase about two- to maximally threefold in 
the postprandial state. Furthermore, it is estimated that only about 10% of 
secreted GLP-1 remains active by the time it reaches the central circulation due 
to the abundant degradation by DPP-IV (figure 3) [56]. The narrow range of 
plasma GLP-1 concentrations is contrasted by its wide dynamic range of action. 
In healthy humans, GLP-1 infusion reaching supraphysiologic concentrations 
five- to six-fold higher than postprandial levels results in an almost exponential 
insulinotropic effect [57]. In addition there is experimental data suggesting that 
infusion of GLP-1 at a dose mimicking physiological postprandial levels is not 
able to stimulate insulin secretion in a canine model [58]. Whether a systemic 
Figure 3: Rapid degradation of 
GLP-1 after secretion from L-
cells (from Holst 2007 [56]). 
DPP-IV activity is present in the 
tissue surrounding the L-cell and 
the endothelium. It can be 
estimated that only 25% of active 
GLP-1 reaches the liver and 
further degradation leave only 
about 10-15% uncleaved by the 
time it reaches the circulation. 
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infusion of GLP-1 into humans in an allegedly physiological range is 
insulinotropic, is under debate [59]. In addition, the clinical effectiveness of DPP-
IV inhibitors despite the only moderate increase in circulating active levels of 
GLP-1 has further challenged the classical model of a humoral endocrine 
mechanism of action of GLP-1 [60].  
Hence, alternative models of GLP-1 action have been proposed and there is 
compelling evidence that GLP-1 might mediate its incretin effect in a 
neuroendocrine fashion (figure 4). Nakabayashi et al. have shown that GLP-1r 
signaling in the portal vein of rats augments the firing of hepatic vagal afferents 
and pancreatic vagal efferents, suggesting a neuroendocrine signal originating in 
the portal vein to stimulate insulin secretion from pancreatic β-cells [61]. In 
another study in rats it was demonstrated that a bolus of GLP-1 and glucose into 
the portal vein induces a robust insulinotropic effect that was almost abolished by 
administration of the ganglionic blocker chlorisondamine [62]. The insulinotropic 
action of a bolus of GLP-1 into the jugular vein was not affected by 
chlorisondamine treatment and led to a similar insulin release as portal GLP-1. It 
was concluded that GLP-1 can mediate insulin release both directly in the 
pancreatic islet as well as via a nervous mechanism triggered in the hepatoportal 
system [62]. A study by Burcelin et al. showed in mice that antagonism of the 
GLP-1r with exendin(9-39) in the portal vein but not the femoral vein reduced the 
potency of portal glucose to stimulate its own clearance (hepatoportal glucose 
sensor), while GLP-1 infusion had no such effect. It was suggested that there is a 
constitutive activation of the GLP-1r in the portal vein in the fasting state that is 
necessary for glucose sensing. Interestingly insulin levels increased with the 
portal GLP-1 infusion but the differences in glycemia did not allow estimating its 
contribution to the incretin effect [63]. In addition various canine studies with 
portal vein glucose and GLP-1 infusion showed consistent effects on peripheral 
glucose uptake. This effect seems to be dependent on portal but not systemic co-
infusion of glucose and in this setting GLP-1 does not change pancreatic 
hormone release [64-67].  
Previous studies in our laboratory showed that the GLP-1r is expressed in vagal 
afferent neurons and immunohistochemistry revealed co-localization of 
synaptophysin and GLP-1r in the portal vein of rats. Furthermore, a low-dose 
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Figure 4: Alternative model of 
GLP-1 action. Endogenous GLP-1 
gets secreted from intestinal L-cells 
and acts on GLP-1r in the hepatic 
portal vein. Vagal afferents transmit 
the GLP-1 signaling to neurons in 
the hindbrain from where visceral 
efferents mediate insulin secretion 
from pancreatic β-cells. 
infusion of the GLP-1r antagonist [desHis1, Glu9]exendin-4 into the portal vein but 
not the jugular vein impaired tolerance to oral glucose in rats. Thus, it was 
concluded that portal vein GLP-1r signaling is required for normal glucose 
tolerance (figure 4). Because glycemia was different between the two 
experimental conditions, the effect of portal GLP-1 antagonism on insulin release 
was not further interpretable [68]. 
1.6 Hypothesis: GLP-1 released from the gut into the portal vein 
mediates insulin secretion from pancreatic β-cells through a 
neuroendocrine mechanism via afferents in the hepatoportal 
bed  
While most of these studies show that neuroendocrine GLP-1r signaling in the 
portal vein is essential for glucose tolerance and interfering with it by local 
antagonism or vagal denervation interferes with glucose disposal, none have 
proven that the most prominent action of GLP-1, namely mediating the incretin 
effect, depends on this mechanism. Particularly there is no study that compares 
the effect of GLP-1 infusion into the portal vein with infusion into the jugular vein 
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during isoglycemic conditions that allows comparing insulin secretion in response 
to this intervention. 
Therefore, we hypothesized that site specific infusion of GLP-1 into the portal 
vein would result in higher plasma insulin concentrations during a hyperglycemic 
clamp than jugular infusion of the same dose of GLP-1.  
1.7 Hypothesis II: Pharmacological DPP-IV inhibition will result in a 
similar insulinotropic potency of portal and jugular GLP-1 
As a secondary hypothesis we tested an alternative model whereby portal GLP-1 
is more susceptible to degradation by DPP-IV in the hepatoportal bed where the 
enzyme is highly expressed. In this model the insulinotropic effect of portal GLP-1 
would be weaker than peripherally administered peptide, and pharmacological 
inhibition of DPP-IV would result in similar GLP-1 plasma concentrations in the 
arterial circulation with equal insulinotropic potency of portal and jugular GLP-1.  
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2 Material and methods 
2.1 Animals 
Experiments were performed on male Long Evans rats with a mean body weight 
of 270-300 g, delivered from Harlan Laboratories Inc. (Indianapolis, IN – USA) 
directly to the animal facility at the Genome Research Institute of the University of 
Cincinnati. The animals had ad libitum access to food and water and were fed a 
pelleted chow diet (Teklad; Harlan, Madison, WI – USA). They were housed in 
individual cages in a vivarium with constant temperature (22°C) and were on a 
12/12-hour light/dark-cycle from 6:00 to 18:00 daily. 
Starting on the day of arrival rats had immediate contact with the researchers 
involved in the handling of the animals and the experiments. Rats were weighed 
and handled daily, usually in the morning.  
Beginning one week after arrival at our facility rats underwent surgery 
(section 2.3). During post-surgical recovery the rats were continuously handled 
and weighed daily and their body weight was monitored until they reached their 
pre-surgical body weight. Rats suffering consistent weight loss after surgery were 
fed wet chow, mostly resulting in increased food intake and facilitating recovery. If 
animals had signs of dehydration they were given a subcutaneous injection of a 
balanced electrolyte solution (Normosol®, Pfizer Inc., New York City, NY – USA) 
to improve well-being. Experiments were performed only on fully recovered, 
healthy rats. Health was assessed by monitoring of behavior, food and water 
intake, and general appearance (e.g. rough fur). 
Rats were fasted approximately 15 hours before the experiments having free 
access to water. On the day of the clamp experiment rats were weighed and 
subsequently brought to the room where the experiments took place. There they 
were able to adjust to the new environment for 20-40 minutes. During the 
experiments the animals were conscious and freely moving at all times. 
After the clamp rats were fed and brought back to their housing facility. On the 
following day the animals were examined and weighed to ensure full recovery 
from the experiment. 
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All experiments were approved by the University of Cincinnati Internal Animal 
Care and Use Committee and carried out in accordance to the Association for 
Assessment and Accreditation of Laboratory Animal Care-approved facilities 
conforming to National Institutes of Health and U.S. Department of Agriculture 
regulations. 
2.2 Materials 
All catheters were prepared manually in our laboratory as described below before 
the surgeries. 
2.2.1 Carotid catheter 
For the carotid artery polyethylene (PE) catheters were used as PE is a stronger 
and more resistant material compared to silicone tubing. The PE-50 was 
produced by Instech Solomon (Plymouth Meeting, PA – USA) and had an inner 
diameter of 0.058 cm and an outer diameter of 0.096 cm. 
Catheters were all cut 20 cm long with a scalpel and 4 cm from the tip a small 
bubble was placed by heating up the PE. To avoid inner collapsing a steel wire 
was inserted into the catheter before. The bubble would help to secure the 
catheter into the carotid artery. The catheters were sterilized by gas or alcohol 
and before their use they were flushed with sterile 0.9% saline (Baxter, Deerfield, 
IL – USA).  
The length of the catheter part inserted into the carotid artery would vary based 
on the individual rat’s body weight: 2.7 cm /300 g and additional 0.1 cm per 20 g 
of body weight. 
2.2.2 Jugular catheter 
For the jugular vein catheter silicone tubing from Braintree Scientific Inc. 
(Braintree, MA – USA) was used. The catheters had an inner diameter of 
0.063 cm and an outer diameter of 0.119 cm and were 20 cm long. With liquid 
silicone a small bubble was made 4.2 cm from the tip to secure the catheter 
internally to the jugular vein. 
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2.2.3 Portal catheter 
Silicone tubing (Braintree Scientific Inc.) was also used for the portal vein 
catheter as it is a softer and gentler material. The catheters had an inner 
diameter of 0.050 cm and an outer diameter of 0.093 cm and were 28 cm long. 
The inner tip was beveled to facilitate insertion in the quickly collapsing portal 
vein. With liquid silicone a small bubble was placed 1 cm from the tip to help 
secure the catheter to the portal vein. 5 cm from the inner tip a Dacron mesh 
(Braintree Scientific Inc.) with 0.5 cm diameter was attached around the catheter 
with liquid silicone. This mesh was sutured to the abdominal wall to further secure 
a correct placement of the portal catheter. 
2.3 Surgery 
2.3.1 General preparation 
A sterile table cloth was placed on the operating table, all sterile instruments and 
materials were then placed on it. Under the sterile table cloth a heating pad was 
placed covered by two layers of gauze to avoid over-heating and burning. 
The rats received general anesthesia through a standard Isoflurane inhalation 
(99%Iso/ml, Abbott Laboratories, North Chicago, IL – USA). Rats were placed in 
a transparent box with an oxygen and isoflurane supply. After approximately 
5 minutes they were taken out and shaved on the neck, abdomen and back with 
a commercial razor. 
The shaved spots were then disinfected with povidone-iodine antiseptic 
(Betadine®, Purdue Pharma L.P., Stamford, CT – USA). The rats were placed on 
the operating table with their head towards the surgeon for insertion of the carotid 
and jugular catheter and opposite to the surgeon for the portal catheter. The 
nasal mask for anesthesia was moved during surgeries according to the rat’s 
position. 
Rats were injected with 160 µl of bupivacaine 0.25% (Hospira, Lake Forest, IL – 
USA) on the neck where the catheters exited the skin to minimize foreign body 
sensation. Additionally the animals were injected subcutaneously with 300 µl 
buprenorphine (Burpenex®, 0.3 mg/ml, Hospira) and intraperitoneally with 210 µl 
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enrofloxacin 2.27% (Baytril®, Bayer Healthcare, Shawnee Mission, KS – USA) as 
a perioperative antibiotic prophylaxis. 
The rat’s eyes were protected from ulcera by placing petrolatum ophthalmic 
ointment (Puralube® Vet Ointment, Pharmaderm, Melville, NY – USA) between 
the eyelids with a Q-tip.  
2.3.2 Placement of carotid catheter 
Access to the neck was through a midline incision. After careful, blunt dissection 
of the sternohyoid and the sternocleidomastoid muscles the carotid artery and its 
common path with the vagal nerve was identified. With curved forceps the carotid 
artery was dissected and separated from the vagal nerve and the curved forceps 
were placed underneath the carotid artery. The carotid artery was tied off 
cranially with a non-absorbable 4-0 silk-suture (Tyco Health Care, Norwalk, CT – 
USA) and 2 further open sutures underneath the vessel were placed. The vessel 
was perforated with a 21 gauge needle (BD, Franklin Lakes, NJ – USA) and the 
catheter was inserted with the help of a plastic introducer (BD). The catheter was 
further introduced with the curved forceps until the bubble of the catheter was 
reached. On the opposite, external side of the catheter was a 3 ml syringe (BD) 
filled with 0.9% saline (Baxter) to immediately flush the line. The catheter was 
then clamped off to avoid retrograde filling of the catheter with blood. 
Subsequently the 2 sutures lying underneath the vessel around the artery were 
tied around the catheter to secure it. The distal suture that tied off the upper part 
of the artery was used to additionally secure the catheter. 
Finally, a 16 gauge tunneling needle (Roboz Surgical Instrument Co., 
Gaithersburg, MD – USA) was used to tunnel the catheter underneath the rat’s 
skin and to perforate it on the back between the shoulder blades, where the 
animal was previously shaved.  
2.3.3 Placement of jugular catheter 
Using the same access as for the carotid artery catheter the tissue lateral of the 
sternocleidomastoid muscle was dissected until the jugular vein was visible. The 
jugular vein was elevated by dissecting the tissue underneath with the curved 
forceps and then clamped distally with help of a mosquito hemostat. The vein 
was perforated with a curved 20 gauge needle (BD) and the lumen of the vein 
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was held open with sharp jeweler’s-forceps while simultaneously inserting the 
catheter holding it with the curved forceps and making it advance up to the 
bubble. After confirming that the catheter was patent by drawing blood and 
flushing it with saline the vessel was ligated around the catheter both proximal 
and distal of the bubble with non-absorbable 4-0 silk (Tyco Health Care). The 
hemostat was then removed. The catheter was closed with a 1 cm long steel wire 
and tunneled subcutaneously to the back with the help of the 16 gauge needle. 
Finally the skin was sutured with antibacterial 4-0 Vicryl Plus (Ethicon, 
Somerville, NJ – USA) by single interrupted stitches. 
2.3.4 Placement of portal catheter 
A 5 cm long midline abdominal incision was performed starting at the xiphoidal 
process. The abdominal wall as opened by lifting it with the rat-tooth forceps to 
avoid injury to the inner organs and cutting along the linea alba. A warm, wet, 
sterile 4x4 gauze was inserted on the right side of the abdomen to keep a good 
access to the abdominal cavity because no retractors were used. With sterile, wet 
Q-tips the bowel was mobilized and laid into warm wet sterile gauze to the left 
side of the animal. 
After identifying the portal vein a wet piece of 2x2 gauze was placed under the 
liver to gently keep it lifted. After careful preparation and cleaning of connective 
tissue around the portal vein a small hole was made with a 25 gauge needle 
(BD). Subsequently the tip of the catheter was inserted by holding it with forceps 
and pushing it into the vein up to the bubble. The catheter was secured using 7-0 
non-absorbable suture (Ethicon) to the omentum. With a mosquito hemostat the 
abdominal wall on the right side of the animal was perforated and the distal part 
of the catheter was pulled through it until the second bubble and the mesh were 
in place on the abdominal wall. The catheter was then tunneled to the back of the 
animal with help of the 16 gauge needle and closed with a 1 cm long steel wire. 
The intestine was carefully replaced and the muscular abdominal wall was 
sutured with single interrupted stitches with antibacterial 4-0 Vicryl Plus. The skin 
incision was closed by also suturing with 4-0 Vicryl and single interrupted stitches 
and by additionally stapling with Michael-clips (Roboz Surgical Instrument Co.). 
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All catheters were pulled through a larger, thicker, 5 mm long piece of silicone 
tubing (Braintree Scientific Inc.) holding them together and were flagged and 
color-coded with a small piece of tape. The tape would simultaneously prevent 
the lines from slipping back under the skin. The lines were then all flushed with 
heparinized saline (100 U/ml heparin in 0.9% saline (both Baxter). 
2.4 Hyperglycemic clamps with site-specific GLP-1 infusion 
2.4.1 General Set-Up 
Before the experiment the clamp room had to be prepared. On a regular table the 
infusion pumps (11 Plus, Harvard Apparatus, Holliston, MA – USA) for glucose 
and GLP-1, 1 ml Syringes for blood sampling, 4x4 non-sterile gauze, glucometers 
and test strips, a mini centrifuge, labeled Eppendorf tubes, and an ice bucket 
were placed. A second table with lower height (2 x the height of the shoebox 
container) was placed next to the experimental table and the rat was placed on 
top of it in its container. The general clamp setup is depicted in figure 5. 
Catheter adapters were prepared with PE-60 tubing (Instech Solomon) with an 
inner diameter of 0.0762 cm and an outer diameter of 0.1220 cm. To check the 
patency of all catheters a 20 cm piece of PE tubing was attached to each 
catheter on the back of the animal. To connect the tubing with the catheters a 
metal connector was used for the jugular and portal vein (Braintree Scientific Inc.) 
and silicone tubing for the carotid artery catheter (Braintree Scientific Inc., inner 
diameter 0.0762 cm and outer diameter 0.1650 cm). On the other side of the 
tubing a syringe with a 21 gauge needle was placed and heparinized saline 
(0.9% with 100 U/ml heparin) was used to flush the catheter. Animals were used 
for the clamp experiment if all 3 catheters would allow both injection and drawing 
blood from them.  
If all catheters were patent they were connected to the prepared infusion 
catheters made of PE-60. The jugular and the portal catheter were connected to 
a 2-channel swivel (Instech Solomon) placed on the top of the cage. This would 
allow the rat to move freely within the cage during the clamp experiment 
(figure 6). The other side of the swivel was connected to the respective syringe 
pumps with the same tubing. The carotid catheter was connected separately and 
had to be untwisted manually when the rat moved.  
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2.4.2 Glucose infusion, peptide preparation and blood samples 
For the variable glucose infusion of the hyperglycemic clamp a commercial 
Dextrose-50% solution (Baxter) was diluted 1:1 with saline 0.9% (Baxter) to 
receive D-25% in a 10 ml syringe.  
In all experiments an additional constant amount of glucose (D-20%, Baxter) was 
infused into the portal vein at a rate of 4 mg/kg/min. This was done to rule out 
that the portal GLP-1r acts only in a glucose-dependent manner. Physiologically 
GLP-1 and glucose as well as other nutrients appear almost simultaneously in 
the portal vein after a meal.  
After putting the rat back into the cage allowing it another 10 minutes to adapt to 
the environment, a baseline blood sample was drawn.  
Figure 5: General clamp setup. Freely moving rat in a shoebox container. 
Infusion pumps are set up on the experimental table and plastic tubing is 
connected with the indwelling catheters externalized on the rat’s back. 1 ml 
syringes and glucometers are prepared for drawing blood and measuring blood 
glucose. 
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The syringe for the peptide infusion was prepared from a stock of frozen GLP-1 
aliquots with 2.5 µg/ml (Bachem, Torrence, CA – USA) stored at -20°C. The 
peptide was gently thawed on ice before the experiment. To avoid that the 
peptide sticks to the large plastic surface (syringe, tubing, catheters) 200 µl of 
blood from the rat was taken together with the first baseline sample and mixed 
with the peptide in the final 5 ml infusion syringe (protein coating).   
Now the infusion catheters were primed up to where the catheters entered the 
rat’s skin so that the glucose and peptide infusions would reach the circulation 
immediately after the syringe pumps were started.  
Blood samples were taken from the carotid artery catheter that was connected to 
PE-60 tubing with a needle on the other end. For every blood sample first the 
saline for flushing the tubing was removed with a 1 ml syringe until the catheter 
was completely filled with blood. To avoid diluted samples 0.5 ml blood was 
drawn into a separate 1 ml syringe but not discarded. Then the actual samples 
were drawn into another 1 ml syringe. For measuring glucose only a few drops of 
blood were drawn; for measuring insulin 0.3 ml of whole blood was taken. 
Figure 6: Conscious and freely moving rat during clamp experiment. The 
catheters are connected through a swivel that would allow untwisting the infusion 
lines multiple infusion syringes are inserted into the pumps without interruption. 
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Afterwards 0.5 ml of blood previously removed was reconstituted in saline and 
infused into the carotid artery to avoid hypovolemia and acute anemia and the 
catheter was flushed with 0.7 ml of heparinized saline (20 U/ml).  
Insulin samples were put into sterilized, heparinized (1000 U/ml) Eppendorf 
tubes. Samples were immediately centrifuged for 2 minutes at 6000 rpm (2000 g) 
in a mini centrifuge (Research Products International Corporation, Mount 
Prospect, IL, USA) and approximately 150 µl of plasma was pipetted into a pre-
labeled empty Eppendorf tube and stored on ice. To avoid progressive anemia 
throughout the clamp the red blood cells (RBC) were re-suspended with saline 
0.9% and reinfused after the next blood draw. 
After all preparations were finished another baseline sample was drawn 
immediately before the glucose infusions were started (time point 0). The glucose 
infusion for the hyperglycemic clamp was started with an initial dose of 
90 mg/kg/min for the first 2 minutes, followed by 25 mg/kg/min for another 
3 minutes and 20 mg/kg/min thereafter given through the jugular catheter. This 
dose was the result of previous dose-finding studies performed at our laboratory 
to induce a square-wave of hyperglycemia (data not shown).  
Blood glucose was measured in 5-minute intervals from 0-120 minutes and the 
glucose infusion rate (GIR) adjusted accordingly by an ad-hoc algorithm to 
maintain constant hyperglycemia. Glucose was measured using a standard 
bedside glucometer (Freestyle Flash, Abbott Diabetes Care, Alameda, CA – 
USA) in duplicate (with 2 glucometers) for each time point and the mean of both 
measurements was calculated.  
Blood draws for insulin samples were taken at 0, 10, 30, 40, 50, 55, 60 minutes 
during the first hour of the clamp before the GLP-1 infusion was started.   
2.4.3 GLP-1 infusion 
After 60 minutes of constant hyperglycemia the graded GLP-1 infusion was 
started to go either into the portal or jugular vein. Hyperglycemia was maintained 
for the remainder of the experiment (until 120 min) with the variable glucose 
infusion. From 60-80 minutes GLP-1 was infused at a rate of 1.5 µg/kg/h. From 
80-100 minutes the rate was increased to 2.5 µg/kg/h, followed by 5 µg/kg/h from 
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100-120 minutes. The doses were chosen based on previous experiments 
conducted in our laboratory (data not shown).  
During the infusion of GLP-1, samples for plasma insulin measurements were 
taken at 70, 75, 80, 90, 95, 100, 110, 115, and 120 minutes (3 samples for each 
GLP-1 dose). 
At the end of the hyperglycemic clamp all catheters were clamped with hemostats 
between the rat and the swivel and cut off distally of the hemostat. The rats were 
then taken out of the cage and the tubing was removed where the connectors 
were. After flushing the catheters with heparinized saline (100 U/ml) they were 
closed with the steel wires. Rats were then fed. 
Plasma samples for insulin measurements were immediately taken to the 
laboratory, put in boxes and frozen at -20 C until they were assayed within 1-
4 weeks.  
2.5 Hyperglycemic clamps with DPP-IV inhibition 
To test the hypothesis whether GLP-1 infused into the portal vein could be 
protected from rapid degradation by pharmacological DPP-IV inhibition, we 
performed the same experiments after administration of vildagliptin.  
For this experiment rats were injected with 10 mg vildagliptin (suspended in 1 ml 
of saline) intraperitoneally. Vildagliptin was kindly provided by Dr. Bryan Burkey 
of Novartis (Cambridge, MA – USA). The injections were performed with a 
23 gauge needle (BD) on conscious animals in their housing room 30 minutes 
before the hyperglycemic clamp. Afterwards the animals were moved to the room 
where the experiments took place. The experimental setup was then identical to 
that of hyperglycemic clamps without DPP-IV inhibition as described above. 
2.6 Arterial plasma concentrations of active GLP-1(7-36) after site 
specific infusion into the portal or jugular vein 
Because of the limited amount of blood that could be taken during the 
hyperglycemic clamps without severe hemodilution no plasma samples for 
measuring GLP-1 concentrations were taken during these experiments. Instead 
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GLP-1 infusion into either the portal or jugular vein with sampling from the carotid 
artery was performed in a separate cohort of rats.  
In general the setup was similar to the hyperglycemic clamps but there was no 
infusion of glucose. An infusion of GLP-1 was prepared as described in detail 
above. The GLP-1 syringe was put into the syringe pump and attached to one 
arm of the swivel. The GLP-1 infusion was given either into the portal or jugular 
vein. A baseline sample of 1 ml was taken from the carotid artery catheter 
immediately before the GLP-1 infusion was started (time point 0). From 0-20 min 
GLP-1 was infused at a rate of 2.5 µg/kg/h and from 20-40 min at a rate of 
5 µg/kg/h. 1 ml samples were taken at the end of each infusion step (time points 
20 and 40 minutes).  
All animals received an intraperitoneal injection of either saline or the DPP-IV 
inhibitor vildagliptin 30 minutes prior to start of the GPL-1 infusion (1 ml).  
Whole blood samples for GLP-1 measurements were immediately placed in 
chilled Eppendorf tubes prepared with a proteinase-inhibiting cocktail (100 µl per 
tube, EDTA (0.5 M), heparin (800 U/ml), aprotinin (0.28 mM), and diprotin A 
(0.066 mM)) to avoid peptide degradation. Tubes were kept on ice until the end of 
the experiment and then brought immediately to the laboratory. There they were 
spun at 10,000 rpm at 4°C for 10 minutes in a tabletop centrifuge (Fisher Thermo 
Scientific, Waltham, MA – USA). Plasma samples were pipetted into pre-labeled 
Eppendorf tubes, put in a box and stored at -80°C until they were assayed.  
2.7 Insulin RIA 
Insulin assays were performed using a commercially available RIA-kit from 
Millipore (Millipore Corporation, Billerica, MA – USA) following the manufacturer’s 
instructions except of the use of a specific rabbit insulin antibody as previously 
described [69].   
2.8 GLP-1 ELISA 
GLP-1(7-36) plasma concentrations were measured using a commercially 
available ELISA for active GLP-1 (Millipore Corporation) according to the 
manufacturer’s instructions.  
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2.9 Statistical Analysis 
Comparison of the cohorts and the parameters of the hyperglycemic clamps were 
done by a student’s t-test for unpaired samples with normal variance (table 1). 
The effects on hyperglycemia, glucose infusion rate and insulin concentrations 
during the hyperglycemic clamp in response to the dose of GLP-1 and infusion 
site (portal vs. jugular) were compared by 2-way ANOVA for repeated measures. 
If there was a significant effect of the infusion site, Bonferroni post-tests were 
performed to compare the effect of portal vein vs. jugular vein infusion (tables 2-
4). A p-value of <0.05 was considered statistically significant. The results are 
expressed as mean ± standard error of the mean (SEM) for the different cohorts. 
Analysis and graph plotting was done using GraphPad Prism 5.0 (GraphPad 
Software Inc., San Diego, CA – USA). 
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3 Results 
3.1 Surgery 
A total of approximately 240 rats was purchased for surgeries and experiments. 
Almost all of these animals underwent the surgical placement of catheters. Of 
these approximately 50 animals underwent clamp procedures and about 
20 animals were used for measurement of arterial GLP-1 plasma levels. The 
majority of the latter animals were already used for a previous clamp procedure, 
after which they were allowed to recover for at least one week.  
There are multiple reasons for the relatively large number of operated animals 
compared to actual clamp experiments. It should be noted that both, the 
placement of three catheters including the portal vein in one surgical procedure, 
as well as the hyperglycemic clamps, had to be established newly at the 
laboratory. Naturally there was a learning curve, particularly regarding the 
surgery with decreasing rates of casualties and drop outs over time. Few rats 
died from apnea during anesthesia. In some cases the placement of the 
catheters led to dissection of the vessels and consequently fatal hemorrhage. 
Particularly the placement of the portal vein catheter was challenging and rats 
were at risk of bleeding out quickly. The portal vein was not clamped during the 
procedure to avoid manipulation of the vessel and the surrounding vagal 
afferents.  
As described above, clamps were only performed in healthy rats that fully 
regained their pre-surgical body weight. Some rats presented with neurological 
symptoms during the recovery period indicating a stroke and therefore had to be 
euthanized. Some animals scratched or bit holes in their catheters during the 
recovery period despite the careful externalization of the catheters between the 
scapulae and individual housing.  
Rats could not be used for the clamp procedures unless all three catheters were 
fully patent (easy flushing and aspiration of blood). Despite the heparin block of 
the catheters, clotting was a recurring problem, particularly with the portal vein 
catheter that had the smallest inner diameter.  
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A few hyperglycemic clamps had to be terminated because a rat had irreversibly 
twisted the infusion catheters preventing a continuous and stable infusion of 
glucose or GLP-1 and thus affecting the hyperglycemic clamp and the reliability 
of the insulin response to GLP-1. Even fewer animals bit holes into the infusion 
catheters during the clamp procedure that were not fixable and led to abortion of 
the experiment or fatal bleeding. Some rats showed focal neurological symptoms 
during the experiments indicating a stroke which led to immediate termination of 
the clamp.  
3.2 Hyperglycemic clamps 
Hyperglycemic clamps were performed in 10 rats with portal vein (pv) and 10 rats 
with jugular vein (jv) infusion of GLP-1. The body weight at the day of the clamp 
was very similar in both cohorts with 315.1±5.9 g and 314.8±5.2 g (pv vs. jv, 
p=0.97). Also the levels of fasting glucose (97.6±4.9 mg/dl vs. 95.9±2.9 mg/dl, 
p=0.76), average glucose during the hyperglycemic clamp (212.1±3.5 mg/dl vs. 
206.3±2.5 mg/dl, p=0.19) and glucose over basal (114.5±6.0 mg/dl vs. 110.4±2.7 
mg/dl, p=0.54) did not differ significantly between the cohorts. The coefficient of 
variation (CV) for the duration of the hyperglycemic clamps were equally low in 
both groups with 8.7±0.6 % and 8.8±0.5 %, respectively (p=0.96).  
After administration of ip vildagliptin clamps were performed in 9 rats with infusion 
of GLP-1 into the portal vein and in 12 rats with infusion of GLP-1 into the jugular 
vein. Body weight at the day of the clamp was not significantly different with 
335.2±5.8 g and 319.7±8.4 g (pv vs. jv, p=0.17). Similar to the experiments 
without the DPP-IV inhibitor, fasting glucose (99.9±4.8 mg/dl vs. 98.1±2.7 mg/dl, 
p=0.72), average glucose during the hyperglycemic clamp (201.2±1.4 mg/dl vs. 
202.7±1.1 mg/dl, p=0.38) and glucose over basal (101.2±1.4 mg/dl vs. 104.6±2.4 
mg/dl, p=0.49) did not differ significantly between the cohorts. The coefficient of 
variation (CV) was 8.6±0.7 % in the pv-group and 9.4±0.7 % in the jv-group 
(p=0.38). The results are summarized in table 1.  
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3.3 Effect of portal vs. jugular vein GLP-1 infusion 
Glycemia, glucose infusion rates and insulin concentrations during the constant 
hyperglycemic clamp and concomitant infusion of increasing doses of GLP-1 into 
the portal or jugular vein are summarized in table 2.  
Glucose concentrations decreased significantly in both cohorts (pv 
216.2±4.0 mg/dl to 201.4±7.4 mg/dl; jv 212.4±3.2 mg/dl to 198.8±3.3 mg/dl) 
towards the end of the hyperglycemic clamp with higher doses of GLP-1 
(p<0.0001 for dose) but with no significant difference between portal and jugular 
vein infusion (p=0.1568 for infusion site) (figure 7a).  
  
Table 1: baseline and clamp characteristics 
 Portal Vein GLP-1 
(N=10) 
Jugular Vein GLP-1 
(N=10) 
p-Value 
Body weight (g) 315.1±5.9 314.8±5.2 0.97 
Fasting glucose (mg/dl) 97.6±4.9 95.9±2.9 0.76 
Clamp glucose (average) 
(mg/dl) 
212.1±3.5 206.3±2.5 0.19 
Glucose over basal 
(mg/dl) 
114.5±6.0 110.4±2.7 0.54 
CV – Clamp (%) 8.7±0.6 8.8±0.5 0.96 
With DPP-IV inhibition (Vildagliptin) 
 
Portal Vein GLP-1 
(N=9) 
Jugular Vein GLP-1 
(N=12) 
p-Value 
Body weight (g) 335.2±5.8 319.7±8.4 0.17 
Fasting glucose (mg/dl) 99.9±4.8 98.1±2.7 0.72 
Clamp glucose (average) 
(mg/dl) 
201.2±1.4 202.7±1.1 0.38 
Glucose over basal 
(mg/dl) 
101.2±1.4 104.6±2.4 0.49 
CV – Clamp (%) 8.6±0.7 9.4±0.7 0.38 
Mean ± SEM for cohorts undergoing the clamp procedure. Differences between the 
animals receiving portal vs. jugular vein infusion of GLP-1 were compared using a two-
sided ttest for unpaired cohorts with equal variances. A p<0.05 was considered 
statistical significant. None of the parameters differed significantly between portal 
and jugular vein GLP-1 infusion. 
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Table 2: glucose, glucose infusion rate (GIR) and insulin during clamp 
Glucose (mg/dl) 
 Portal Vein GLP-1 
(N=10) 
Jugular Vein GLP-1 
(N=10) 
p-Value 
Hyperglycemia 216.2±4.0 212.4±3.2 ns 
+ GLP-1 1.5 µg/kg/h 219.3±4.0 216.1±2.9 ns 
+ GLP-1 2.5 µg/kg/h 218.9±6.5 201.0±3.4 ns 
+ GLP-1 5.0 µg/kg/h 201.4±7.4 198.8±3.3 ns 
RM 2-way ANOVA: Dose (p<0.0001) of GLP-1 but not infusion site (p=0.1568) had a 
significant impact on plasma glucose levels.  
Glucose infusion rate (mg/kg/h) 
 
Portal Vein GLP-1 
(N=10) 
Jugular Vein GLP-1 
(N=10) 
p-Value 
Hyperglycemia 27.7±3.4 31.2±2.6 ns 
+ GLP-1 1.5 µg/kg/h 28.0±3.3 30.3±2.5 ns 
+ GLP-1 2.5 µg/kg/h 28.5±3.3 35.1±2.6 ns 
+ GLP-1 5.0 µg/kg/h 34.5±3.8 54.8±3.6 ns 
RM 2-way ANOVA: Dose (p<0.0001) of GLP-1 but not infusion site (p=0.0582) had a 
significant impact on the glucose infusion rate. 
Insulin (pmol/l) 
 Portal Vein GLP-1 
(N=10) 
Jugular Vein GLP-1 
(N=10) 
p-Value 
Hyperglycemia 282±33 318±29 ns 
+ GLP-1 1.5 µg/kg/h 300±36 378±28 ns 
+ GLP-1 2.5 µg/kg/h 396±44 679±112 ns 
+ GLP-1 5.0 µg/kg/h 577±71 1178±235* <0.05 
RM 2-way ANOVA: Dose (p<0.0001) of GLP-1 and infusion site (p=0.0207) had a 
significant impact on plasma insulin levels. Bonferroni post-hoc testing revealed 
significantly higher insulin levels during infusion of GLP-1 into the jugular vs. portal 
vein at a dose of 5 µg/kg/h 
* indicates a p<0.05 
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Figure 7: Glucose (A), glucose infusion rate (B), and insulin (C) during 
hyperglycemic clamp. Line graphs (left) depict infusion of portal (red circles) or 
jugular (blue dots) GLP-1 infusion starting at time point 60 min, with increasing 
doses (61-80 min 1.5 µg/kg/h; 81-100 min 2.5 µg/kg/h; 101-120 min 5.0 µg/kg/h). 
Bar graphs (right) depict average glucose (top), glucose infusion rate (middle), 
and insulin (bottom) levels during infusion of portal (white with red border) or 
jugular (blue) infusion of GLP-1. Hypergl.(ycemia) reflects the average values 
from 50 to 60 min before the GLP-1 infusion was started. GLP-1 infusion in to 
the jugular vein at the highest dose had a significantly greater effect on insulin 
plasma concentrations than portal infusion (*p<0.05).  
C 
A p=0.1568 
 
B p=0.0582 
 
p=0.0207 
 
* 
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Also the glucose infusion rate (GIR) to maintain constant hyperglycemia 
increased significantly (pv 27.7±3.4 mg/kg/min to 34.5±3.8 mg/kg/min; jv 
31.2±2.6 mg/kg/min to 54.8±3.6 mg/kg/min) with higher doses of GLP-1 infusion 
(p<0.0001). Portal vein GLP-1 infusion tended to result in lower GIR than jugular 
vein GLP-1 infusion (p=0.0582) but this difference did not reach statistical 
significance (figure 7b). 
With increasing doses of GLP-1, plasma insulin concentrations raised 
significantly during both portal (282±33 pM to 577±71 pM) and jugular vein 
(318±29 pM to 1178±235 pM) infusion (p<0.0001). Infusion of GLP-1 into the 
portal vein lead to significantly lower insulin levels than GLP-1 infusion into the 
jugular vein (p=0.0207). Post-hoc analyses revealed a significantly lower insulin 
concentration during infusion of GLP-1 at a dose of 5 µg/kg/h into the portal vein 
when compared to infusion of the same amount into the jugular vein (p<0.05) 
(figure 7c).  
3.4 Effect of DPP-IV inhibition on portal and jugular vein GLP-1 
infusion 
Glycemia, glucose infusion rates and insulin concentrations during hyperglycemic 
clamps with prior inhibition of DPP-IV activity by vildagliptin and portal vs. jugular 
vein infusion of GLP-1 are summarized in table 3.  
Hyperglycemia during the clamps was significantly altered by GLP-1 dose 
(p<0.0001) but not by infusion site (p=0.9257) with a similar reduction of glycemia 
under 2.5 µg/kg/h GLP-1 infusion (pv 213.3±2.6 mg/dl to 192.0±4.3 mg/dl; jv 
208.5±3.4 mg/dl to 195.8±3.3 mg/dl) but higher glycemia towards the end of the 
clamp with higher infusion rates of glucose (pv 210.9±3.8 mg/dl; jv 
214.8±2.4 mg/dl).  
GIR increased significantly with higher doses of GLP-1 (p<0.0001) with no 
difference between pv and jv infusion of the peptide (p=0.2680). The GIR 
increased constantly with each dose of GLP-1 from 36.8±2.1 mg/kg/min to 
51.3±3.1 mg/kg/min during portal infusion of GLP-1 and from 40.0±1.9 mg/kg/min 
to 54.2±4.2 mg/kg/min during jugular GLP-1 infusion. 
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Table 3: glucose, glucose infusion rate (GIR) and insulin during clamp 
after DPP-IV inhibition 
Glucose (mg/dl) 
 Portal Vein GLP-1 
(N=10) 
Jugular Vein GLP-1 
(N=10) 
p-Value 
Hyperglycemia 213.3±2.6 208.5±3.4 ns 
+ GLP-1 1.5 µg/kg/h 205.6±3.9 203.6±3.2 ns 
+ GLP-1 2.5 µg/kg/h 192.0±4.3 195.8±3.3 ns 
+ GLP-1 5.0 µg/kg/h 210.9±3.8 214.8±2.4 ns 
RM 2-way ANOVA: Dose (p<0.0001) of GLP-1 but not infusion site (p=0.9257) had a 
significant impact on plasma glucose levels. 
Glucose infusion rate (mg/kg/h) 
 
Portal Vein GLP-1 
(N=10) 
Jugular Vein GLP-1 
(N=10) 
p-Value 
Hyperglycemia 36.8±2.1 40.0±1.9 ns 
+ GLP-1 1.5 µg/kg/h 36.9±2.9 41.7±2.3 ns 
+ GLP-1 2.5 µg/kg/h 47.5±3.2 53.1±3.6 ns 
+ GLP-1 5.0 µg/kg/h 51.3±3.1 54.2±4.2 ns 
RM 2-way ANOVA: Dose (p<0.0001) of GLP-1 but not infusion site (p=0.2680) had a 
significant impact on the glucose infusion rate. 
Insulin (pmol/l) 
 Portal Vein GLP-1 
(N=10) 
Jugular Vein GLP-1 
(N=10) 
p-Value 
Hyperglycemia 543±59 672±135 ns 
+ GLP-1 1.5 µg/kg/h 932±168 1569±264 ns 
+ GLP-1 2.5 µg/kg/h 1535±366 2310±340 ns 
+ GLP-1 5.0 µg/kg/h 1822±300 1788±425 ns 
RM 2-way ANOVA: Dose (p<0.0001) of GLP-1 but not infusion site (p=0.2799) had a 
significant impact on the insulin concentration. 
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Figure 8: Glucose (A), glucose infusion rate (B), and insulin (C) during 
hyperglycemic clamp with inhibition of DPP-IV. Line graphs (left) depict 
infusion of portal (red circles) or jugular (blue dots) GLP-1 infusion starting at 
time point 60 min, with increasing doses (61-80 min 1.5 µg/kg/h; 81-100 min 
2.5 µg/kg/h; 101-120 min 5.0 µg/kg/h). Bar graphs (right) depict average glucose 
(top), glucose infusion rate (middle), and insulin (bottom) levels during infusion of 
portal (white with red border) or jugular (blue) infusion of GLP-1. 
Hypergl.(ycemia) reflects the average values from 50 to 60 min before the GLP-
1 infusion was started. There was no significant difference between insulin 
concentrations with portal or jugular GLP-1 infusion. 
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After DPP-IV inhibition insulin plasma concentrations increased significantly with 
higher doses of GLP-1 (p<0.0001) but unlike the previous experiments without 
the DPP-IV inhibitor there was no significant difference between portal and 
jugular vein GLP-1 infusion (p=0.2799). While insulin levels increased stepwise 
from 543±59 pM during hyperglycemia only, to 932±168 pM with 1.5 µg/kg/h 
GLP-1, to 1535±366 pM with 2.5 µg/kg/h GLP-1 and ultimately 1822±300 pM with 
5 µg/kg/h of GLP-1 when infused into the portal vein, insulin plasma 
concentrations increased from 672±135 pM (no GLP-1) to a maximum of 
2310±340 pM with the second dose of GLP-1 (2.5 µg/kg/h) in order to fall down to 
1788±425 pM with the highest dose of GLP-1 (5 µg/kg/h) when it was infused into 
the jugular vein. When the 2-way ANOVA for RM was performed until the end of 
the 2.5 µg/kg/h infusion rate of GLP-1 the jv infusion tended to result in higher 
insulin than the pv infusion (p=0.1020).  
Numerically the insulin plasma concentrations were higher in the experiments 
with the DPP-IV inhibitor as can be expected. Because the experiments with and 
without vildagliptin were done in separate cohorts and there was no placebo 
given during the first set of experiments, no direct statistical comparison between 
those two conditions was performed.  
3.5 Plasma levels of GLP-1(7-36) during portal or jugular vein 
infusion 
In a separate cohort plasma concentrations of active GLP-1(7-36) was measured 
in the arterial blood stream under all four conditions (pv vs. jv infusion ± DPP-IV 
inhibition). Without vildagliptin basal GLP-1 was 2.6±0.4 pM (pv) and 3.3±0.9 pM 
(jv), respectively. Both dose (p<0.0001) and infusion site (p=0.0001) had 
significant impact on the measurement of the GLP-1 plasma concentration. Post-
hoc analysis revealed that jv infusion resulted in significantly higher GLP-1 
plasma levels than pv infusion both at a rate of 2.5 µg/kg/h (jv 43.6±5.0 pM vs. pv 
14.3±2.4 pM, p<0.001) and at a rate of 5 µg/kg/h (jv 80.9±3.4 pM vs. 
36.6±2.8 pM, p<0.001).  
With previous administration of intraperitoneally vildagliptin basal plasma levels of 
active GLP-1 were similarly elevated to 7.0±2.5 pM (pv) and 7.7±2.2 pM (jv) in 
both cohorts. 2-way ANOVA revealed again a significant effect of both dose 
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(p<0.0001) and infusion site (p=0.0081 for pv vs. jv). Bonferroni post-hoc testing 
showed no significant difference of GLP-1 plasma concentrations at an infusion 
rate of 2.5 µg/kg/h (pv 47.1±12.3 pM vs. jv 116.7±27.9 pM, ns) but a highly 
significant difference at an infusion rate of 5 µg/kg/h (pv 184.8±35.7 pM vs. jv 
443.2±66.4 pM, p<0.01) (table 4).  
 
Table 4: GLP-1 (7-36) plasma concentration (pmol/l) during portal and 
jugular vein infusion 
without DPP-IV inhibition 
 Portal Vein GLP-1 
(N=5) 
Jugular Vein GLP-1 
(N=5) 
p-Value 
Baseline 2.6±0.4 3.3±0.9 ns 
2.5 µg/kg/h 14.3±2.4 43.6±5.0*** p<0.001 
5.0 µg/kg/h 36.6±2.8 80.9±3.4*** p<0.001 
RM 2-way ANOVA: Dose (p<0.0001) of GLP-1 and infusion site (p<0.0001) had a 
significant impact on the GLP-1 plasma concentration. Bonferroni post test revealed 
significantly higher plasma GLP-1 levels after infusion of both 2.5 and 5 µg/kg/h GLP-1 
into the jugular vs. portal vein (p<0.001 for both doses). *** indicates a p<0.001 
with DPP-IV inhibition 
 
Portal Vein GLP-1 
(N=5) 
Jugular Vein GLP-1 
(N=6) 
p-Value 
Baseline 7.0±2.5 7.7±2.2 ns 
2.5 µg/kg/h 47.1±12.3 116.7±27.9 ns 
5.0 µg/kg/h 184.8±35.7 443.2±66.4** p<0.01 
RM 2-way ANOVA: Dose (p<0.0001) of GLP-1 and infusion site (p<0.0081) had a 
significant impact on the GLP-1 plasma concentration. Bonferroni post test revealed 
significantly higher plasma GLP-1 levels after infusion of 5 µg/kg/h GLP-1 into the 
jugular vs. portal vein (p<0.01). ** indicates a p<0.01 
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Figure 9: Arterial plasma concentrations active GLP-1 during infusion of 
GLP-1(7-36)amide into the portal (red/white) or jugular vein (blue). The 
graph on the left depicts GLP-1 levels between portal or jugular GLP-1 infusion 
with previous intraperitoneal injection of saline. The graph to the right depicts 
GLP-1 levels between portal or jugular GLP-1 infusion with previous 
intraperitoneal injection of vildagliptin. RM 2-way ANOVA shows with and without 
vildagliptin highly significant effects of both dose and infusion site (p<0.0001). 
Post-hoc tests showed significantly higher GLP-1 levels in the jugular vs. portal 
vein. *** indicates a p<0.001; ** indicates a p<0.01 
*** *** 
** 
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4 Discussion 
 
In recent years evidence against an endocrine mechanism of action of GLP-1 
grew [56]. Thus, it was hypothesized that GLP-1 mediated insulin release from 
pancreatic β-cells is a consequence of a combined neuro-humoral signaling 
circuit in which GLP-1 released into the portal circulation acts via GLP-1r in nerve 
endings of vagal afferents in the hepatoportal vein. To test this hypothesis an 
equimolar amount of synthetic GLP-1 was infused either into the portal or jugular 
vein during constant hyperglycemia and a larger insulin response to the 
intraportal GLP-1 infusion was expected. Contrary to the hypothesis, GLP-1 
infusion into the jugular vein resulted in a more potent insulin secretion than an 
equimolar infusion of GLP-1 into the portal vein. This was paralleled by 
significantly higher arterial plasma concentrations of active GLP-1 after infusion 
of the peptide into the jugular vs. the portal vein. Because degradation of GLP-1 
across the hepatoportal bed after infusion of the active peptide into the portal vein 
seemed to contribute significantly to this result the experiments were repeated 
with the potent inhibitor of DPP-IV activity vildagliptin. Also with DPP-IV inhibition 
the arterial plasma concentrations of GLP-1 were significantly higher with jugular 
vs. portal vein infusion of the peptide and resulted in numerically higher insulin 
levels.  
There are several possible explanations as to why our hypothesis was not 
confirmed. First of all, the hyperglycemic clamp and portal infusion of GLP-1 is 
not a physiological setting. As mentioned above, most studies used a GLP-1r 
antagonist or vagal denervation in order to show that this results in disturbance of 
a physiological response to intestinal feeding [67, 68]. Although we co-infused 
glucose into the portal vein to simulate the physiological appearance of glucose 
from the gut and GLP-1 in the portal vein, the larger portion of glucose to 
generate constant systemic hyperglycemia was infused into the jugular vein. 
Thus there was no negative arterial to portal glucose gradient, which is seen 
normally after a meal. Previous studies in dogs suggest that this gradient is 
necessary for glucose and GLP-1 to mediate increased glucose utilization [66]. 
However, it is unclear to which extend this holds true for rodents and humans and 
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if this also applies to changes in insulin secretion was not part of the study by 
Johnson et al. 
Another explanation could be that splanchnic afferents that transport the vagal-
pancreatic neuroendocrine loop originate proximal from where we placed our 
catheter. In fact, there is already significant degradation of GLP-1 by the time it 
reaches the portal vein (figure 3) and afferent GLP-1r carrying vagal fibers have 
been described also in the intestine surrounding GLP-1 secreting L-cells [56]. 
This hypothesis could explain why studies inhibiting the neural signal in a 
physiological oral meal test results in impaired glucose tolerance [70]. Moreover, 
a study by Hayes et al. showed that specific denervation of the common hepatic 
branch of the vagus did not alter glucose tolerance and feeding behavior in 
response to the GLP-1r antagonist exendin-9 while complete subdiaphragmatic 
vagotomy did [71]. Interestingly, most studies finding positive effects on GLP-1r 
action used a paradigm antagonizing GLP-1 effects instead of agonism at the 
receptor. They concluded that vagal afferents mediate the glucose lowering 
effects of GLP-1 in a paracrine fashion through nerve endings surrounding the L-
cells rather than receptors in the portal vein. On the other hand such a hypothesis 
would be contrary to many positive experiments with infusion of GLP-1 [61, 62] or 
the antagonist [63, 68] into the portal vein. 
A study published by Nishizawa et al. also tested the hypothesis that portal GLP-
1 would mediate insulin secretion from the pancreas in a neuroendocrine fashion 
[72]. However, they used a different study design. First, they measured portal 
concentrations of GLP-1 and glucose following a meal. Then they showed that a 
brief low dose infusion of GLP-1 together with a high dose of glucose would result 
in a higher insulin release than infusion of glucose alone and this effect was 
abolished by vagotomy. Infusion of a slightly higher GLP-1 dose resulted in an 
insulinotropic effect that was not completely reversed by vagotomy, suggesting 
that spill-over of portal GLP-1 was responsible for this effect. Finally infusion of 
the higher dose into the jugular vein resulted in an insulinotropic effect that was 
not changed by vagotomy. Although the authors did not directly compare the 
insulin levels in response to portal and jugular GLP-1 infusion, the levels were 
about 2-fold higher with a jugular infusion of the same dose. An infusion of the 
lower dose of GLP-1 was not tested in the jugular vein. The authors concluded 
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that in a physiological setting (portal glucose infusion, low physiological levels of 
GLP-1) GLP-1 mediates insulin release mainly through a neuroendocrine signal 
originating in the portal vein, whereas higher doses or administration into the 
jugular vein directly act on pancreatic β-cells [72]. There are multiple important 
differences that may explain the conflicting results with our study. First of all, in 
the experiments by Nishizawa et al. glucose was completely infused into the 
portal vein, whereas we used only a low dose glucose infusion in the portal vein 
and the hyperglycemic clamp was maintained through jugular vein glucose 
infusion. Second, we used a hyperglycemic clamp of a long duration with a 
graded GLP-1 infusion rather than a short term infusion with a single dose. Also 
in the study by Nishizawa et al., the specific effect of portal GLP-1 became only 
apparent after vagotomy. We refrained from vagotomy because compared to 
jugular vein infusion there was clearly no prominent insulinotropic effect in the 
portal vein. Finally, there was no dose-response trial and direct comparison of 
GLP-1 infusion into either the portal or jugular vein in this previously published 
study. While there was no direct comparison of the insulinotropic effect between 
the jugular and portal vein infusion, the graphic result confirm our finding that 
equimolar doses of GLP-1 infusion into the jugular vein elicits a higher insulin 
response than portal vein infusion, a consequence of more intensive degradation 
of GLP-1 in the hepatoportal bed [72]. Furthermore, using a DPP-IV inhibitor to 
quantify the contribution of GLP-1 inactivation in the hepatoportal bed during 
pharmacological intervention is unique to our study.  
Interestingly the doses of GLP-1 used in the experiments by Nishizawa and ours 
differed greatly. The dose of 1.5 µg/kg/h corresponds to 7.6 pmol/kg/min and 
5 µg/kg/h to about 25 pmol/kg/min. Nishizawa et al. used 1 pmol/kg/min as a low 
and 3 pmol/kg/min as a high dose [72]. Despite the fact that our lowest dose was 
>2-fold higher than the high dose of Nishizawa et al. there was no significant 
effect on insulin secretion either in the portal or jugular vein. Previous studies 
infusing GLP-1 into the portal vein have employed 5 pmol/kg/min [63] 
corresponding to about 1 µg/kg/h. In our pilot studies using doses of 1 µg/kg/h 
and lower there was no insulinotropic effect, so we decided to use a graded 
infusion ranging from a subthreshold dose to a pharmacologic range (data not 
shown). Although our dose of 1.5 µg/kg/h is about 8-fold higher than the 
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1 pmol/kg/min in the study by Nishizawa et al. showing a portal vein specific 
effect on insulin secretion, this dose was clearly in a subthreshold range in our 
experiments. Extrapolating the plasma levels of active GLP-1 with infusion of 
2.5 µg/kg/h into the portal vein to the lower dose, also suggests that we targeted 
a physiological range. A possible explanation would be that Nishizawa et al. used 
a more purified peptide than we did, although both studies used the same peptide 
producer (Bachem, USA vs. Bachem Switzerland). Nevertheless, the peptide 
concentrations we used are similar to what has previously been published in 
dose response studies of GLP-1 [73, 74]. 
Regarding neurally mediated effects of endogenous GLP-1 or pharmacologic 
GLP-1r activation even the most recent studies employing state-of-the-art genetic 
engineering show conflicting results. Using chemogenetics and optogenetics 
Williams et al. showed that the vast majority of GLP-1r carrying afferent vagal 
neurons have their nerve endings within the muscle layer, do not participate in 
nutrient sensing, do not respond to pharmacologic administration of a GLP-1r 
agonist, and seem to primarily function as gastrointestinal mechanoreceptors 
[75]. Similarly, Sisley and colleagues showed that neuron specific knockout (both 
centrally and peripherally) of the GLP-1r did not alter food intake, body weight or 
glucose tolerance in a physiological setting. The weight reducing effects of the 
GLP-1r agonist liraglutide however required the brain GLP-1r but not a functional 
GLP-1r on peripheral neurons [76]. This was confirmed by another study that 
mapped in great detail the relevant brain regions activated by liraglutide and did 
also not involve vagal GLP-1r signaling [77]. On the other hand, Krieger et al. 
showed that lentiviral knockdown of GLP-1r in the nodose ganglia of rats 
increased postmeal hyperglycemia and reduced insulin but did not alter 
responses to an oral glucose tolerance test. In this study changes in gastric 
emptying may have had a significant impact on the findings. Similarly to the 
previous studies there was no effect on long-term food intake and body weight 
[78]. However, very conflicting results were published by Iwasaki et al. who 
showed that the non-caloric sweetener D-allulose stimulated endogenous GLP-1 
release, which reduced food intake, body weight, and glycemia through GLP-1r 
signaling in vagal afferents in genetic mouse models of complete or isolated 
vagal GLP-1r knockdown [79]. 
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Taken together it remains unclear whether our results are accounted for because 
GLP-1 does not exert insulinotropic (incretin) effects through a neuroendocrine 
signal in the portal vein, or if an unphysiological setup prevented us from showing 
a positive effect. Interestingly, similarly conflicting results have been shown in 
regards to GLP-1’s effects on food intake and satiety. While some studies have 
found GLP-1 infusion into the portal vein to reduce food intake more potently than 
systemic infusion [80] others have not [81, 82]. 
While it was not possible to show that a low dose infusion of GLP-1 into the portal 
vein exerts an insulinotropic effect in this study the results contribute further to 
the body of evidence that challenges an endocrine mode of action of GLP-1. In 
addition these results do not support that enhancement of circulating GLP-1(7-
36)amide is responsible for the insulinotropic effects of DPP-IV inhibition. Infusion 
of GLP-1 at a dose of 1.5 µg/kg/h into the portal vein was clearly not 
insulinotropic and at 2.5 µg/kg/h resulted in a non-significant 40% increase in 
insulin plasma concentrations (one-way ANOVA for portal GLP-1 infusion in 
response to dose). The GLP-1 plasma concentration measured in another cohort 
but corresponding to the dose of 2.5 µg/kg/h in the portal vein, was 
14.3±2.4 pmol/l and thus represented a 6.0±1.2-fold increase over basal 
(2.6±0.4 pmol/l). Although we did not measure postprandial arterial plasma 
concentrations of active GLP-1 in this cohort, this relative increment is more 
pronounced than what is regularly seen after a meal. On the other hand DPP-IV 
inhibition with vildagliptin increased the plasma concentrations of GLP-1 to 
7.0±2.4 pmol/l in the fasting state, which corresponds to about a 3-fold increase 
vs. no vildagliptin. Similarly to what is seen in human studies [83] DPP-IV 
inhibition resulted in a 2-fold increase of plasma insulin during the hyperglycemic 
clamp before the GLP-1 infusion was started (543±59 pmol/l vs. 282±33 pmol/l, 
unpaired t-test p<0.001). Looking at the relative potency to stimulate insulin 
secretion and the corresponding GLP-1 plasma concentrations seen after 
infusion of synthetic GLP-1 vs. enhancing endogenous GLP-1 action it becomes 
apparent that circulating GLP-1 may neither be mediating the incretin effect nor 
the glucose lowering actions of DPP-IV inhibition.  
Despite of the use of the potent pharmacological DPP-IV inhibitor vildagliptin, 
there remained a significant difference of active GLP-1 reaching the arterial 
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circulation between portal and jugular infusion of the peptide (table 4, figure 9). 
As mentioned above, insulin concentrations were about twice as high during 
constant hyperglycemia with vildagliptin and further amplified by a factor of 3-4 
when GLP-1 was infused in either site. With exception to the unexpected drop in 
insulin levels during the highest dose of GLP-1 infusion into the jugular vein, 
there was a clear left shift in the dose response curve of both portal and jugular 
vein infusion of GLP-1 with DPP-IV inhibition. So the gap between plasma insulin 
levels in response to either portal or jugular vein infusion of GLP-1 remained 
present (with the exception to the highest dose), even though this was not 
statistically significant.  
Together this supports the role of the hepatoportal bed as a major site of GLP-1 
degradation as previously described by Hansen et al. in pigs [84, 85]. It also 
demonstrates that even with pharmacological DPP-IV inhibition there remains 
significant DPP-IV action to degrade active GLP-1. Previous studies showed a 
>80%-reduction of plasma DPP-IV activity with vildagliptin and good protection 
from degradation of intraperitoneally injected GLP-1 [86, 87]. Hence, membrane 
bound DPP-IV (i.e. on the endothelium) seems to remain a potent factor of 
incretin degradation in the hepatoportal circulation under pharmacological DPP-
IV inhibition. Again, this observation of intensive GLP-1 degradation in the liver 
despite pharmacological DPP-IV inhibition makes it unlikely that this drug class 
acts primarily through enhancement of circulating GLP-1(7-36) amide released 
from the gut.  
Very elegant studies with genetic models of GLP-1r activity have further shed 
light on the possible insulinotropic mechanism of GLP-1. Lamont et al. created a 
transgenic model, where the human GLP-1r was restored in the pancreatic ductal 
and β-cells on the background of a GLP-1r -/- mouse (Pdx1-hGLP1R:Glp1r -/- 
mice). Thus, there was only a functional GLP-1r present in the pancreas but not 
in the nervous system or other tissues. Interestingly, the pancreatic GLP-1r was 
sufficient to reverse the glucose intolerance seen in GLP-1r -/- mice and 
normalize insulin secretion. This suggests that GLP-1 is acting directly on the 
pancreatic β-cells and does not require additional receptor activation, like a GLP-
1r in the portal vein [88]. Unlike glucose tolerance, effects of the GLP-1r agonist 
exendin-4 on food-intake, hindbrain activation, or gastric emptying were not 
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restored by isolated pancreatic expression of the GLP-1r. These results however 
are at odds with another transgenic model, where the GLP-1r has been 
specifically knocked out in the β-cells of the pancreas with intact GLP-1r signaling 
in other tissues [89]. Here the results were more complex with differential effects 
of β-cell GLP-1r knockdown during oral and parenteral glucose administration. 
While the β-cell GLP-1r was not necessary to allow normal oral glucose tolerance 
and glucose lowering of DPP-IV inhibition, the insulinotropic effect of 
intraperitoneal or intravenous GLP-1 was severely blunted. Another recent study 
in transgenic mice helps to bring together the results of Lamont et al. [88] with the 
well-founded skepticism towards an endocrine mode of action of endogenous 
GLP-1. More and more evidence points towards a significant and physiological 
relevant production of GLP-1 in pancreatic α-cells [55]. In this context Chambers 
et al. silenced proglucagon expression in mice (thus preventing GLP-1 
production) but were able to restore expression specifically in the gut or pancreas 
[90]. While recovery of proglucagon expression in the intestine was able to 
almost completely restore circulating GLP-1 levels it did not have an impact on 
the metabolic phenotype. More importantly, using the GLP-1r antagonist exendin-
9 did not impair glucose tolerance with functional GLP-1r and intestinally secreted 
GLP-1. However, salvage of proglucagon expression only in pancreatic α-cells 
resulted in a clear effect of GLP-1r blockade with exendin-9 towards decreased 
glucose tolerance. The authors drew the legitimate conclusion that not intestinal 
GLP-1 stimulates insulin secretion through β-cell GLP-1r, but activation happens 
in a paracrine fashion by locally produced GLP-1 from the α-cells.  
Of course, there are limitations with transgenic mouse models and it is unclear if 
the same mechanisms hold true for rats or even humans. Despite the highly 
conserved amino acid sequence of GLP-1 across different species and even 
more of the identical GLP-1r in many mammals including rodents, dogs, pigs, 
non-human primates, and humans, there seem to be some species specific 
differences of the GLP-1r signaling [91, 92]. In addition, knockout models tend to 
develop mechanisms compensating for loss-of-function, as for example seen with 
the single incretin receptor knockout mice [44]. Furthermore knockdown of GLP-1 
expression cannot be separated from disturbing the signaling of all proglucagon 
derived peptides including glucagon, which is a potent mediator of metabolic 
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effects. Nevertheless, all those studies support our findings that circulating GLP-1 
plasma concentrations in a physiological range do not correlate well with its 
insulinotropic effect and that other mechanisms than portal GLP-1r activation may 
mediate insulin secretion.  
Another unexpected finding was the drop of plasma insulin concentrations seen 
with the highest dose of GLP-1 in conjunction with DPP-IV inhibition. The almost 
exponential increase in arterial plasma concentrations of active GLP-1 with 
infusion of synthetic peptide into the jugular vein while protecting its degradation 
with vildagliptin would have suggested a parallel increase in plasma insulin with a 
continuous left shift of the dose response curve between portal vs. jugular vein 
infusion. A possible explanation is that maximal stimulation of insulin release was 
already achieved with the second highest dose of GLP-1 corresponding to a 
drastically supraphysiologic plasma concentration of about 120 pmol/l. In fact 
some studies have shown that acute administration of high doses of the GLP-1r 
agonist exendin-4 causes paradoxical hyperglycemia in rats, possibly mediated 
by activation of the sympathetic nervous system [91, 93]. The immensely high 
plasma concentration of GLP-1(7-36)amide of about 450 pmol/l seen with the 
highest dose infusion into the jugular vein could be sufficient to induce symptoms 
of aversion, activate the sympathetic nervous system and possibly limit the 
insulin release from β-cells [94]. Because this unexpected drop in insulin towards 
the end of the clamp was seen consistently across the whole cohort a random 
effect or technical problems with the GLP-1 infusion seem unlikely.  
We employed a complex and labor intensive study design to test our hypothesis. 
The hyperglycemic clamp is the most rigorous experiment to test insulin 
secretion. However, a more physiological setting with primary glucose infusion 
into the portal vein may have been better for the purpose of the study. Following 
the previous publications using GLP-1r antagonists and the hypothesis of a 
constitutive activated receptor, portal vein infusion of exendin-9 may have shown 
interesting results. On the other hand the incretin effect should be mediated by 
increases in GLP-1 and not decreased receptor agonism. Although our study was 
generally well powered, some results reached only borderline significance (GIR, 
insulin in clamps with vildagliptin, GLP-1 plasma levels) and a bigger sample size 
would have likely shown clearer results. Still, with greater power the general 
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conclusions most likely would not have differed from the reported results. Finally, 
measurements of GLP-1 plasma concentrations during the clamp experiments 
would have allowed generating individual dose-response curves and correlations 
for portal and jugular GLP-1 infusion. Unfortunately, it was not possible to draw 
the necessary amount of blood during the hyperglycemic clamp without causing 
severe anemia and significantly elevate stress levels in this experimental setup 
with conscious animals.  
The importance and physiological relevance of portal vein GLP-1r signaling 
remains elusive and study results are conflicting. While some studies have found 
effects of disrupted portal vein GLP-1r signaling, others - including this one - have 
not shown an incretin effect specific for portal GLP-1. However, particularly the 
studies involving genetic disruption of neurally mediated GLP-1r signaling make it 
difficult to argue towards a relevant physiological action. On the other hand, this 
study is in line with the growing body of evidence against the endocrine mode of 
action of GLP-1 and alternative models like intra-islet GLP-1r signaling seem 
worthwhile to follow-up on. Most importantly, the effort should be directed 
towards transporting these studies of physiological effects from pre-clinical 
models into humans to further explore and optimize the treatment of diabetes and 
obesity.  
In summary, we were not able to show a direct insulinotropic effect through GLP-
1r activation in the hepatoportal bed via vagal afferents, as we hypothesized. 
However, we demonstrated that high, pharmacological doses of GLP-1 need to 
be infused into the portal vein to reach significant arterial plasma concentrations 
of the active peptide and consequently insulin release from pancreatic β-cells. 
We also confirmed that the hepatoportal bed is a major site of GLP-1’s 
inactivation in vivo and furthermore retains significant activity towards GLP-1 
degradation in the presence of a pharmacological DPP-IV inhibitor. Altogether, 
our findings give further support to the reservations about an exclusive endocrine 
mechanism of action of intestinally released GLP-1 and pharmacological DPP-IV 
inhibition.  
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5 Summary 
 
Glucagon-like peptide-1 (GLP-1) is an enteral hormone secreted by L-cells in the 
small and large bowel after meal ingestion. GLP-1 stimulates insulin secretion in 
a glucose-dependent manner and accounts together with glucose-dependent 
insulinotropic peptide (GIP) for the incretin effect. GLP-1 mediates its effects 
through a specific receptor (GLP-1r) expressed in a variety of tissues including 
the β-cells of the pancreatic islets. The commonly accepted endocrine model of 
the insulinotropic action of GLP-1 suggests that the peptide hormone is secreted 
from the intestine after luminal contact of nutrients and reaches the β-cell through 
the systemic circulation. However, its short half-life due to rapid degradation by 
Dipeptidylpeptidase-IV (DPP-IV), and the barely detectable plasma 
concentrations even in the postprandial state, are conflicting with an endocrine 
mechanism of action and alternative models have been investigated. Several 
studies have been indicating an essential role of the GLP-1r in the portal vein and 
the involvement of a neuroendocrine signal to stimulate insulin secretion. 
This study was the first to compare the effect of portal GLP-1 infusion with 
systemic infusion through the jugular vein during constant hyperglycemia in rats, 
allowing a direct comparison of insulin levels. We hypothesized that GLP-1 
infusion into the portal vein would result in higher plasma insulin levels during a 
hyperglycemic clamp than a jugular infusion of the same dose. Catheters were 
placed into the carotid artery, jugular, and portal vein during general anesthesia. 
Hyperglycemic clamps were performed in conscious, freely moving rats with a 
graded infusion of GLP-1 (1.5 – 5 µg/kg/h) into the portal or jugular vein. To test 
the degree of hepatic degradation of GLP-1, the same experiments were 
repeated with a DPP-IV inhibitor. In addition, arterial plasma concentrations of the 
active peptide were measured after site-specific infusion of GLP-1 with or without 
a DPP-IV inhibitor.  
Contrary to our hypothesis, GLP-1 infusion into the jugular vein resulted in higher 
insulin concentrations than an equimolar dose of GLP-1 in the portal vein, 
contradicting an important role of portal GLP-1r signaling for insulin secretion. 
This also suggests that the hepatoportal bed is a major site of GLP-1 inactivation 
and GLP-1 infused into the portal vein is more susceptible to degradation by 
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DPP-IV than an infusion into the jugular vein. After DPP-IV inhibition the insulin 
response to portal and jugular GLP-1 infusion did not differ significantly. 
However, there remained a numerically higher insulin response with jugular 
compared to portal GLP-1 infusion and hence a left shift of the dose-response-
curve. Correspondingly, the arterial plasma concentrations of active GLP-1 were 
2-3-fold higher with jugular compared to portal infusion of the peptide and this 
difference persisted even after administration of a potent pharmacological DPP-
IV inhibitor.  
In conclusion, these findings do not support an important role of hepatoportal 
GLP-1r signaling in mediating the incretin effect of GLP-1. However, the clearly 
lower potency of portal compared to jugular GLP-1-infusion to elicit an 
insulinotropic response together with the persistently lower arterial plasma 
concentrations after portal infusion even in the presence of a DPP-IV inhibitor, 
argue against an endocrine mechanism of action of endogenously released GLP-
1. Furthermore, the failure of the DPP-IV inhibitor vildagliptin to protect the 
majority of GLP-1 infused into the portal vein from degradation does not support 
the concept that this drug class acts by augmenting GLP-1 levels in the 
circulation. Other alternatives to an endocrine model of GLP-1 action, like 
paracrine GLP-1 signaling within the islets, seem promising and should be further 
investigated. 
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6 Zusammenfassung 
 
Glucagon-like peptide-1 (GLP-1) ist ein enterales Hormon, das von den L-Zellen 
des Dünn- und Dickdarms nach oraler Nahrungsaufnahme sezerniert wird. GLP-
1 stimuliert glukoseabhängig die Insulinsekretion und vermittelt zusammen mit 
dem Glucose-dependent insulinotropic polypeptide (GIP) den Inkretineffekt. GLP-
1 wirkt über einen spezifischen GLP-1 Rezeptor (GLP-1r), der in einer Vielzahl 
unterschiedlicher Gewebe exprimiert wird, z.B. in den β-Zellen der Langerhans-
Inseln des Pankreas. Der bisher angenommene endokrine Wirkmechanismus 
von GLP-1 sieht vor, dass Nahrungsbestandteile im Lumen des Darms zur 
Sekretion des Peptidhormons in die Zirkulation führen und GLP-1 hierüber an 
seine Rezeptoren auf der β-Zelle gelangt. Allerdings geben die extrem kurze 
Halbwertszeit von GLP-1, aufgrund der raschen Inaktivierung durch 
Dipeptidylpeptidase-IV (DPP-IV), sowie die kaum messbaren postprandialen 
Plasmaspiegel von GLP-1, Anlass an einer endokrinen Wirkweise zu zweifeln 
und alternative Wirkmechanismen wurden erforscht. Mehrere Studien haben 
einem neuroendokrinen Mechanismus, ausgehend von GLP-1r in der Portalvene, 
eine wesentliche Rolle in der Vermittlung des insulinotropen Effekts von GLP-1 
zugeschrieben.  
Die hier beschriebene Studie ist die erste, die die Insulinantwort einer portalen 
GLP-1 Infusion mit der einer systemischen (jugulären) Infusion unter stabilen 
hyperglykämischen Bedingungen vergleicht und damit eine Beurteilung des 
insulinotropen Effekts unabhängig von Glukosespiegeln erlaubt. Unsere 
Hypothese war, dass eine portale Infusion von GLP-1 während eines 
hyperglykämischen Clamps, einen stärkeren insulinotropen Effekt haben würde, 
als die gleiche Dosis in der Jugularvene. Hierfür wurden Long-Evans Ratten 
operativ Katheter in die Arteria carotis, die Jugularvene und die Pfortader 
implantiert. Hyperglykämische Clamps wurden an wachen und sich frei 
bewegenden Tieren durchgeführt und mit einer GLP-1 Infusion mit steigender 
Dosierung (1.5-5 µg/kg/h), wahlweise in die Portal- oder Jugularvene, kombiniert. 
Um das Ausmaß der hepatischen Inaktivierung von GLP-1 zu bestimmen, 
wurden dieselben Clamps nach Gabe eines pharmakologischen DPP-IV-
Hemmers wiederholt. Zudem wurden die arteriellen Plasmaspiegel des aktiven 
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GLP-1 nach Infusion des Peptids in die Portal- oder Jugularvene mit und ohne 
DPP-IV-Hemmer gemessen.  
Im Gegensatz zu unserer Hypothese führte die juguläre GLP-1 Infusion zu 
höheren Insulinspiegeln, als die gleiche Dosis in der Portalvene. Dies spricht 
gegen eine wichtige Rolle des portalen GLP-1r in der Vermittlung des 
insulinotropen Effekts von GLP-1. Darüber hinaus bestätigen die Ergebnisse, 
dass die hepatoportale Zirkulation einen wesentlichen Anteil zum Abbau von 
GLP-1 beiträgt. Unter DPP-IV-Hemmung unterschieden sich die Insulinspiegel 
zwischen portaler und jugulärer Infusion nicht mehr signifikant. Dennoch zeigten 
sich numerisch höhere Insulinkonzentrationen nach jugulärer GLP-1-Infusion 
verglichen mit portaler Infusion und eine entsprechende Linksverschiebung der 
Dosis-Wirkungskurve. Korrelierend dazu waren die arteriellen Plasma-
konzentrationen von aktivem GLP-1 2-3-mal höher wenn es in die Jugularvene 
infundiert wurde. Interessanterweise blieb dieser Unterschied auch nach der 
Gabe eines potenten DPP-IV-Hemmers bestehen. 
Zusammenfassend sprechen die Daten dieser Studie nicht für einen relevanten 
Effekt von GLP-1r in der Portalvene bei der Vermittlung des Inkretineffekts. Ein 
endokriner Mechanismus von endogenem GLP-1 scheint aufgrund des 
ausgeprägten intrahepatischen Abbaus und den entsprechend niedrigeren 
arteriellen Plasmaspiegeln des aktiven Peptids nach portaler Infusion dennoch 
unwahrscheinlich. Die ausgeprägte Inaktivierung von portalem GLP-1 trotz der 
Gabe von Vildagliptin spricht darüber hinaus dagegen, dass DPP-IV-Hemmer 
über zirkulierendes GLP-1 ihre insulinotrope Wirkung vermitteln. Daher scheinen 
Alternativen zu einem endokrinen Wirkmechanismus, wie z.B. eine parakrine 
Wirkung von GLP-1 innerhalb der Langerhans-Inseln, vielversprechend und 
sollten weiter verfolgt werden.  
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